Katarina B. H.
- Country
- Sweden
- Department
- Infektionsektionen
Research Overview
Data & Insights
Has run more than one trial at 0 of 14 partner sites.
Specializations
Breast Cancer Therapeutics
Focused on estrogen‑receptor positive and triple‑negative disease subtypes, exploring neoadjuvant strategies, endocrine extensions, and novel antibody‑drug conjugates.
- neoadjuvant endocrine treatment
- HER2‑targeted therapy
- capecitabine addition
- personalised tamoxifen dosing
- antibody‑drug conjugate combinations
Research integrates molecular profiling to guide therapy selection and improve long‑term outcomes.
Cardiovascular & Heart Failure
Investigates therapeutic modulation of heart failure with preserved ejection fraction and post‑myocardial infarction complications, including thrombus resolution and renal‑cardiac interactions.
- balcicrenone/dapagliflozin combination
- apixaban versus warfarin
- spironolactone initiation
- left ventricular thrombus management
- HF hospitalization reduction
Emphasis on pragmatic registry‑based designs to generate real‑world evidence.
Infectious Disease Management
Addresses antimicrobial strategies for resistant pathogens and viral neuroinvasion, targeting conditions such as extended‑spectrum β‑lactamase urinary infections and tick‑borne encephalitis.
- alternative oral antibiotics for ESBL‑UTI
- remdesivir in tick‑borne encephalitis
- pneumonia treatment pathways
- urinary tract infection bacteremia
- vestibular neuritis steroid trial
Studies prioritize safety and efficacy of novel regimens in acute infectious settings.
Metastatic Prostate Cancer & Targeted Therapy
Explores high‑risk disease after definitive surgery, focusing on androgen deprivation combined with advanced agents and DNA repair pathway inhibition.
- ap‑ligand radiotherapy synergy
- BRCA‑mutated prostate cancer trials
- PSMA‑PET guided progression assessment
- biomarker‑driven treatment allocation
- metastases‑free survival endpoints
Integrates molecular diagnostics to refine therapeutic pathways.
Metabolic & Diabetes‑Related Cardiovascular Risk
Evaluates combined metabolic and cardiovascular interventions in patients with type 2 diabetes, hypertension, and established vascular disease.
- vicadrostat plus empagliflozin
- dapagliflozin‑based heart failure studies
- dual SGLT2‑inhibitor strategies
- cardiovascular death reduction
- urgent heart failure visit prevention
Targets integrated risk reduction across glycemic and hemodynamic domains.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.